查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1726377

美國小分子創新原料藥 CDMO 市場：市場規模、佔有率、趨勢分析（按疾病階段、服務、客戶類型、治療領域和地區）、細分市場預測（2025-2030 年）

U.S. Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report By Stage Type (Preclinical, Clinical, Commercial), By Service, By Customer Type, By Therapeutic Area, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

美國小分子創新者原料藥 CDMO 市場成長與趨勢：

根據 Grand View Research, Inc. 的新報告，美國小分子創新原料藥 CDMO 市場規模預計到 2030 年將達到 126 億美元，2025 年至 2030 年的複合年成長率為 6.0%。

製藥公司外包趨勢的日益成長、小分子藥物需求的不斷成長以及臨床試驗的激增預計將對美國市場產生積極影響。

小分子繼續在全球新療法的開發中發揮關鍵作用。特種藥物正日益推動美國製藥業的成長，尤其是在新興市場，小分子藥物佔特種藥物銷售額的一半以上。此外，提高效率也是製藥外包的關鍵驅動力。隨著製藥公司面臨越來越大的壓力來迅速將新藥推向市場，外包已成為加速藥物開發過程的解決方案。 CDMO 利用其專業知識、經驗和最先進的設施來促進高品質藥品的快速高效生產，使製藥公司能夠滿足其開發時間表。

製藥和生物技術公司擴大選擇 CDMO 服務來利用他們的專業知識。 CDMO 在製造能力方面具有靈活性和擴充性，使製藥公司能夠適應不斷變化的市場需求並縮短新治療方法的上市時間。除了提供專業知識和改進的現金流量管理之外，外包還可以帶來顯著的製造效益，例如降低投資風險。對於早期技術和產品，在產品開發階段建立昂貴的內部製造能力會帶來巨大的風險。同時，外包也是一種規避風險的選擇。

在產品的市場需求建立並被理解之前，外包小原料藥API 是一種受歡迎的策略。例如，2022 年 5 月，Piramal Pharma Limited 的 Pharma Solutions 業務（一家 CDMO）在其位於安大略省奧羅拉的工廠開設了一個新的 API 設施。這個最先進的設施已經開始運作並完成初步生產。

美國小分子創新者原料藥 CDMO 市場：分析概述

  • 按階段分類，臨床部分將在 2024 年佔據市場最大收入佔有率，達到 54.68%。此部分的成長歸因於臨床試驗（I-III 期）活動的增加、小分子開發平臺的不斷成長以及專業知識的不斷增加。
  • 根據客戶類型，預計製藥業將在 2024 年佔據最大的收入佔有率，而藥物開發資金的增加將推動該行業的成長。
  • 根據治療領域，腫瘤學領域在 2024 年佔據了最大的收益佔有率。此外，對先進治療藥物的高研發投入有望最大限度地減輕癌症的疾病負擔，從而推動該行業的成長。
  • 2024年美國市場以西方為主，佔最大銷售佔有率，達33.07%。預計慢性病患病率上升、對原料藥和 CDMO 服務的需求以及醫療保健基礎設施的改善等各種因素將極大地推動市場的發展。

目錄

第1章 分析方法與範圍

第2章執行摘要

第3章 市場促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場趨勢與展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 投資金籌措視角
  • 臨床試驗數量分析（2024年）
    • 各階段臨床試驗總數（2024 年）
    • 依研究設計分類的臨床試驗總數（2024 年）
    • 按主要治療領域分類的臨床試驗總數（2024 年）
  • 技術狀況
    • 小分子創新者將人工智慧融入原料藥 CDMO 市場
  • 定價模式分析
  • 法律規範
  • 產業分析工具
    • 波特五力分析
    • PESTEL 與 SWOT 分析
    • COVID-19影響分析

第4章美國小分子創新原料藥 CDMO 市場：依疾病階段的估計與趨勢分析

  • 細分儀表板
  • 美國小分子創新原料藥 CDMO 市場：依疾病階段變化分析
  • 美國小分子創新原料藥 CDMO 市場：按疾病階段分類的市場規模和趨勢分析（2018-2030 年）
  • 臨床前
  • 臨床
    • 第一階段
    • 第二階段
    • 第三階段
  • 上市

第5章美國小分子創新原料藥 CDMO 市場：依服務估算與趨勢分析

  • 細分儀表板
  • 美國小分子創新原料藥 CDMO 市場：按服務分類的變化分析
  • 美國小分子創新原料藥 CDMO 市場：按服務類型分類的市場規模和趨勢分析（2018-2030 年）
  • 製程開發
    • 臨床前開發
    • 臨床開發
    • 擴大規模最佳化
  • 契約製造
    • 臨床
    • 上市
  • 分析測試和品管
  • 包裝和供應鏈解決方案
  • 其他

第6章美國小分子創新原料藥 CDMO 市場：依顧客類型估算與趨勢分析

  • 細分儀表板
  • 美國小分子創新者原料藥 CDMO 市場：以客戶類型變化分析
  • 美國小分子創新原料藥 CDMO 市場：按客戶類型分類的市場規模和趨勢分析（2018-2030 年）
  • 製藥
    • 小型企業
    • 中型公司
    • 主要企業
  • 生物技術
    • 小型企業
    • 中型公司
    • 主要企業

第7章美國小分子創新原料藥 CDMO 市場：依治療領域的估計與趨勢分析

  • 細分儀表板
  • 美國小分子創新原料藥 CDMO 市場：依治療領域分類的產量分析
  • 美國小分子創新原料藥 CDMO 市場：按治療領域分類的市場規模和趨勢分析（2018-2030 年）
  • 心血管疾病
  • 腫瘤學
  • 呼吸系統疾病
  • 神經病學
  • 代謝紊亂
  • 感染疾病
  • 其他

第8章美國小分子創新原料藥CDMO 市場：按地區分類的商業分析

  • 區域儀表板
  • 市場規模預測及趨勢分析（2018-2030年）
  • 東北
  • 中西部
  • 西
  • 南部

第9章 競爭態勢

  • 公司分類
  • 企業市場分析（2024年）
  • 公司簡介
    • Lonza Group Ltd.
    • Novo Holdings（Catalent, Inc.）
    • Thermo Fisher Scientific, Inc.
    • Siegfried Holding AG
    • Recipharm AB
    • CordenPharma International
    • Samsung Biologics
    • Labcorp
    • Ajinomoto Bio-Pharma Services
    • Piramal Pharma Solutions
    • Jubilant Life Sciences（Jubilant Biosys Limited）
Product Code: GVR-4-68040-297-9

U.S. Small Molecule Innovator API CDMO Market Growth & Trends:

The U.S. small molecule innovator API CDMO market size is anticipated to reach USD 12.60 billion by 2030 and is projected to grow at a CAGR of 6.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Agrowing outsourcing trend among pharmaceutical companies, increasing demand for small molecule drugs, and surge in clinical trials are anticipated to influence the U.S. market positively.

Small molecules continue to play an important role in developing new treatments globally. Specialty medicines are increasingly driving U.S. pharmaceutical growth, particularly in developed markets, with small molecule applications accounting for over half of specialty sales. In addition, enhanced efficiency serves as another pivotal driver for pharmaceutical outsourcing. With mounting pressure on pharmaceutical companies to expedite the introduction of new drugs to the market, outsourcing emerges as a solution to accelerate the drug development process. Leveraging their expertise, experience, and cutting-edge equipment, CDMOs facilitate the swift & efficient production of high-quality drugs, enabling pharmaceutical firms to adhere to their development schedules.

The pharmaceutical/biotechnology companies increasingly opt for CDMO services to leverage their expertise. CDMOs offer flexibility & scalability in manufacturing capacity, allowing pharmaceutical companies to adapt to changing market demands and accelerate time to market for new therapies. In addition to providing extended expertise and assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks. In the context of early-stage technologies and products, establishing expensive in-house capabilities entails substantial risks across the product development phases. At the same time, outsourcing serves as a risk-averse alternative.

The preference for outsourcing small molecule API has grown as an effective strategy until market demand for products becomes well-established and understood. For instance, in May 2022, Piramal Pharma Limited's Pharma Solutions business, a CDMO, inaugurated a new API facility at its site in Aurora, Ontario. This state-of-the-art plant has commenced operations & has completed its initial production runs.

U.S. Small Molecule Innovator API CDMO Market Report Highlights:

  • Based on stage, the clinical segment led the market with the largest revenue share of 54.68% in 2024. The segment growth can be attributed to the rising clinical trial (Phase I-III) activities, growing small molecule development pipeline, and increasing availability of expertise
  • Based on the customer type, the pharmaceutical segment held the market with the largest revenue share in 2024, attributing to rising funding for drug development is propelling segment growth
  • Based on therapeutic area, the oncology segment accounted for the largest revenue share in 2024. The segment is driven by increasing prevalence of cancer in U.S. In addition, high R&D investments in advanced therapeutics to minimize cancer disease burden are expected to boost segment growth
  • West Group dominated the U.S. market with the largest revenue share of 33.07% in 2024. The presence of various factors, such as increasing prevalence of chronic diseases, demand for APIs & CDMO services and improving healthcare infrastructure is expected to drive market significantly

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Purchased Database
    • 1.3.3. GVR's Internal Database
    • 1.3.4. Secondary Sources
    • 1.3.5. Primary Research
  • 1.4. Information or Data Analysis
    • 1.4.1. Information Analysis
    • 1.4.2. Market Formulation & Data Visualization
    • 1.4.3. Data Validation & Publishing
  • 1.5. Model Details
    • 1.5.1. Commodity Flow Analysis (Model 1)
    • 1.5.2. Top Down Market Estimation (Model 2)
    • 1.5.3. Value-Chain-Based Sizing & Forecasting (Model 3)
    • 1.5.4. Multivariate Analysis (Model 4)
  • 1.6. List of Secondary Sources
  • 1.7. List of Abbreviations
  • 1.8. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Investments & Funding Perspective
  • 3.5. Clinical Trials Volume Analysis, (2024)
    • 3.5.1. Total Number of Clinical Trials, by Phase (2024)
    • 3.5.2. Total Number of Clinical Trials, by Study Design (2024)
    • 3.5.3. Total Number of Clinical Trials, by Key Therapeutic Area (2024)
  • 3.6. Technology Landscape
    • 3.6.1. Integration Of AI In Small Molecule Innovator API CDMO Market
  • 3.7. Pricing Model Analysis
  • 3.8. Regulatory Framework
  • 3.9. Industry Analysis Tools
    • 3.9.1. Porter's Five Forces Analysis
    • 3.9.2. PESTEL by SWOT Analysis
    • 3.9.3. COVID-19 Impact Analysis

Chapter 4. U.S. Small Molecule Innovator API CDMO Market: Stage Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Small Molecule Innovator API CDMO Market; Stage Type Movement Analysis
  • 4.3. U.S. Small Molecule Innovator API CDMO Size & Trend Analysis, by Stage Type, 2018 to 2030 (USD Million)
  • 4.4. Preclinical
    • 4.4.1. Preclinical market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Clinical
    • 4.5.1. Clinical market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2. Phase I
      • 4.5.2.1. Phase I market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3. Phase II
      • 4.5.3.1. Phase II market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4. Phase III
      • 4.5.4.1. Phase III market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Commercial
    • 4.6.1. Commercial market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Small Molecule Innovator API CDMO Market: Service Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Small Molecule Innovator API CDMO Market; Service Movement Analysis
  • 5.3. U.S. Small Molecule Innovator API CDMO Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
  • 5.4. Process Development
    • 5.4.1. Process development market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Preclinical development
      • 5.4.2.1. Preclinical development market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Clinical development
      • 5.4.3.1. Clinical development market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Scale-up optimization
      • 5.4.4.1. Scale-up optimization market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Contract Manufacturing
    • 5.5.1. Contract manufacturing market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. Clinical
      • 5.5.2.1. Clinical market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.3. Commercial
      • 5.5.3.1. Commercial market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Analytical Testing and Quality Control
    • 5.6.1. Analytical testing and quality control market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Packaging and Supply Chain Solutions
    • 5.7.1. Packaging and supply chain solutions market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Small Molecule Innovator API CDMO Market: Customer Type Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Small Molecule Innovator API CDMO Market; Customer Type Movement Analysis
  • 6.3. U.S. Small Molecule Innovator API CDMO Size & Trend Analysis, by Customer Type, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceutical
    • 6.4.1. Pharmaceutical market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Small
      • 6.4.2.1. Small market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Medium
      • 6.4.3.1. Medium market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Large
      • 6.4.4.1. Large market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Biotechnology
    • 6.5.1. Biotechnology market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Small
      • 6.5.2.1. Small market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Medium
      • 6.5.3.1. Medium market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Large
      • 6.5.4.1. Large market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Small Molecule Innovator API CDMO Market: Therapeutic Area Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Small Molecule Innovator API CDMO Market; Therapeutic Area Movement Analysis
  • 7.3. U.S. Small Molecule Innovator API CDMO Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
  • 7.4. Cardiovascular Diseases
    • 7.4.1. Cardiovascular diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Oncology
    • 7.5.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Respiratory Disorders
    • 7.6.1. Respiratory disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Neurology
    • 7.7.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Metabolic Disorders
    • 7.8.1. Metabolic disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. Infectious Diseases
    • 7.9.1. Infectious diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.10. Others
    • 7.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. U.S. Small Molecule Innovator API CDMO Market: Regional Business Analysis

  • 8.1. Regional Dashboard
  • 8.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030 (USD Million)
  • 8.3. Northeast
    • 8.3.1. Competitive scenario
    • 8.3.2. Northeast small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. New Jersey
      • 8.3.3.1. Competitive scenario
      • 8.3.3.2. New Jersey small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. New York
      • 8.3.4.1. Competitive scenario
      • 8.3.4.2. New York small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Massachusetts
      • 8.3.5.1. Competitive scenario
      • 8.3.5.2. Massachusetts small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.4. Midwest
    • 8.4.1. Competitive scenario
    • 8.4.2. Midwest small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Illinois
      • 8.4.3.1. Competitive scenario
      • 8.4.3.2. Illinois small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Missouri
      • 8.4.4.1. Competitive scenario
      • 8.4.4.2. Missouri small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. North Carolina
      • 8.4.5.1. Competitive scenario
      • 8.4.5.2. North Carolina small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5. West Group
    • 8.5.1. Competitive scenario
    • 8.5.2. West Group small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. California
      • 8.5.3.1. Competitive scenario
      • 8.5.3.2. California small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. Washington
      • 8.5.4.1. Competitive scenario
      • 8.5.4.2. Washington small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.6. South
    • 8.6.1. Competitive scenario
    • 8.6.2. South small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. Texas
      • 8.6.3.1. Competitive scenario
      • 8.6.3.2. Texas small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. Florida
      • 8.6.4.1. Competitive scenario
      • 8.6.4.2. Florida small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Georgia
      • 8.6.5.1. Competitive scenario
      • 8.6.5.2. Georgia small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Company Market Position Analysis, 2024
  • 9.3. Company Profiles
    • 9.3.1. Lonza Group Ltd.
      • 9.3.1.1. Company overview
      • 9.3.1.2. Financial performance
      • 9.3.1.3. Service benchmarking
      • 9.3.1.4. Strategic initiatives
    • 9.3.2. Novo Holdings (Catalent, Inc.)
      • 9.3.2.1. Company overview
      • 9.3.2.2. Financial performance
      • 9.3.2.3. Service benchmarking
      • 9.3.2.4. Strategic initiatives
    • 9.3.3. Thermo Fisher Scientific, Inc.
      • 9.3.3.1. Company overview
      • 9.3.3.2. Financial performance
      • 9.3.3.3. Service benchmarking
      • 9.3.3.4. Strategic initiatives
    • 9.3.4. Siegfried Holding AG
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Service benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Recipharm AB
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Service benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. CordenPharma International
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Service benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Samsung Biologics
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Service benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Labcorp
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Service benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Ajinomoto Bio-Pharma Services
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Service benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Piramal Pharma Solutions
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Service benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Jubilant Life Sciences (Jubilant Biosys Limited)
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Service benchmarking
      • 9.3.11.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 4 U.S. small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 5 U.S. small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 6 U.S. small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 7 U.S. small molecule innovator API CDMO market estimates and forecasts, by region, 2018 - 2030 (USD Million)
  • Table 8 Northeast small molecule innovator API CDMO market estimates and forecasts, by states, 2018 - 2030 (USD Million)
  • Table 9 Northeast small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 10 Northeast small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 11 Northeast small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 12 Northeast small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 13 New Jersey small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 14 New Jersey small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 15 New Jersey small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 16 New Jersey small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 17 New York small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 18 New York small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 19 New York small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 20 New York small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 21 Massachusetts small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 22 Massachusetts small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 23 Massachusetts small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 24 Massachusetts small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 25 Midwest small molecule innovator API CDMO market estimates and forecasts, by states, 2018 - 2030 (USD Million)
  • Table 26 Midwest small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 27 Midwest small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 28 Midwest small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 29 Midwest small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 30 Missouri small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 31 Missouri small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 32 Missouri small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 33 Missouri small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 34 North Carolina small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 35 North Carolina small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 36 North Carolina small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 37 North Carolina small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 38 West Group small molecule innovator API CDMO market estimates and forecasts, by states, 2018 - 2030 (USD Million)
  • Table 39 West Group small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 40 West Group small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 41 West Group small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 42 West Group small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 43 California small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 44 California small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 45 California small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 46 California small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 47 Washington small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 48 Washington small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 49 Washington small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 50 Washington small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 51 South small molecule innovator API CDMO market estimates and forecasts, by states, 2018 - 2030 (USD Million)
  • Table 52 South small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 53 South small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 54 South small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 55 South small molecule innovator API CDMO market estimates and forecasts, by states, 2018 - 2030 (USD Million)
  • Table 56 Texas small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 57 Texas small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 58 Texas small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 59 Texas small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 60 Florida small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 61 Florida small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 62 Florida small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 63 Florida small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 64 Georgia small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 65 Georgia small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 66 Georgia small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 67 Georgia small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 small molecule innovator API CDMO market, Segmentation
  • Fig. 7 Market driver analysis
  • Fig. 8 Market restraint relevance analysis
  • Fig. 9 Porter's five forces analysis
  • Fig. 10 PESTEL by SWOT analysis
  • Fig. 11 Regional marketplace: Key takeaways
  • Fig. 12 U.S. preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 13 U.S. clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 14 U.S. Phase I market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 U.S. Phase II market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 U.S. Phase III market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 U.S. commercial market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 U.S. process development market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 U.S. preclinical development market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 U.S. clinical development market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 U.S. scale-up optimization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. commercial market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. analytical testing and quality control market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 U.S. packaging and supply chain solutions market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. small pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. medium pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. large pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. biotechnology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. small biotechnology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. medium biotechnology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. large biotechnology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. cardiovascular diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. respiratory disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 U.S. neurology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. metabolic disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. infectious diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Regional Outlook, 2024 & 2030
  • Fig. 44 Northeast small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 New Jersey small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 New York small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Massachusetts small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Midwest small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Illinois small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Missouri small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 North Carolina small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 West Group small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 California small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Washington small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 South small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Texas small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Florida small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Georgia small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)